Movement Disorders Centre - Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
NCT Number: NCT06642519
Gait problems in Parkinson's disease (PD), especially freezing of gait (FOG), greatly affect quality of life. While deep brain stimulation (DBS) is a highly effective treatment for many motor symptoms of PD, it is less effective for, or can even worsen, gait issues. The primary motor cortex (M1) plays a crucial role in the network that controls gait, particularly in initiating movement. Changes in local field potentials (LFPs) from the subthalamic nucleus (STN) are associated with different aspects of gait. However, detecting abnormal brain activity related to FOG requires a method called electrocorticography (ECoG), which has revealed that during FOG, there is increased beta-gamma phase amplitude coupling (PAC) in the M1.
Brain-machine interfaces (BMIs) have shown promise in understanding motor functions by decoding brain activity. It is believed that BMIs could provide both accurate indicators of FOG and targeted treatments for it in PD.
Our objectives are to use a high-density ECoG-based BMI to both record and stimulate brain activity during real-world gait and FOG in PD patients who are undergoing standard DBS procedures. Our goals are to improve our understanding of the brain's role in FOG and normal gait in PD and to develop new treatments based on cortical stimulation.
Aim 1 - Identify gait biomarkers: brain activity from the M1/SMA cortex during different phases of walking and during FOG episodes, both with and without medication will be recorded. Machine learning will be used to identify the brain patterns linked to FOG.
Aim 2 - Use cortical stimulation to stop FOG: Cortical stimulation and its effects on leg and trunk movements will be studied by measuring muscle activity, movement, and posture during different states, such as resting, standing, walking, and during FOG episodes. The type of stimulation which is most effective at stopping FOG will be identified.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
Toronto, Ontario, M5T 2S8, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Studies will be conducted using ECoG, with a bidirectional interface, both recording (aim/phase 1) and stimulating (aim/phase 2), during real-world gait and FOG in PD patients over the course of 7-days of gait experiments.
Time frame: 7-day experiment
The number and duration of FOG episodes either with or without stimulation, including the number/duration of FOG episodes with optimal stimulation.
Time frame: 7-day experiment
The aim is to explore the chronic coupling between cortex and basal ganglia by means of deep brain recordings. This is an exploratory opportunity that will be pursued while carrying out the main aims. However, DBS electrodes will not be turned on to provide stimulation until after they exit the study, after which regular standard-of-care DBS programming will occur.
Time frame: 7-day experiment
It has never been established if individuals with FOG display typical or impaired performance in brain-machine interfaces (BMI) control and whether they can experience phenomena similar to FOG while performing these virtual tasks. This is also an exploratory aim. Participants will be trained to guide virtual effectors (cursors) on a screen using the implanted BMI. The aim is to stablish if standard BMI tasks can trigger FOG-like phenomena. Such occurrence would largely augment the possibility of testing new neuromodulation paradigms to prevent and abolish FOG in laboratory settings.
University of Toronto
Other
Adaptive Cortical Neuromodulation Using a Brain-machine Interface to Treat Freezing of Gait in Parkinson's Disease.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07525973
Basal Ganglia Diseases, Brain Diseases
Isfahan, Iran
View Trial DetailsNCT00001215
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07567599
Basal Ganglia Diseases, Brain Diseases
Belo Horizonte, Minas Gerais, Brazil
View Trial DetailsNCT06104397
Basal Ganglia Diseases, Behavior
Chicago, Illinois, United States
View Trial Details